Asia Dengue Summit 2016

The Asia Dengue Summit 2016 will be held on the 13th to 14th January 2016 at Shangri-La Hotel in Bangkok, Thailand. The Asian Dengue Vaccination Advocacy (ADVA) Group, The Dengue Vaccine Initiative (DVI), the Southeast Asian Ministers of Education Organisation Tropical Medicine and Public Health Network (SEAMEO TROPMED) and the Fondation Mérieux (FMx) will be jointly organising this summit, which is focused on improving strategies for dengue prevention and management by educating stakeholders.

The two-day comprehensive scientific programme is divided into 4 sessions. The first session will provide an overview of dengue prevention and control across Asia and will include the World Health Organisation (WHO) perspective. The current profile of dengue vaccines in pipeline will also be highlighted. The session 2 will evaluate steps involved in planning for a dengue vaccination programme, with an entire talk dedicated to understanding the impact of mathematical modeling on vaccination strategies. The third session will talk about the policies undertaken for the implementation of new vaccine programmes in different Asian countries. The last session will be dedicated to discuss and seek solutions to the practical issues for dengue programmes.

The Asia Dengue Summit 2016 is designed to provide a very broad outlook of dengue management and control because the stakeholders include international organisations such as the World Health Organisation (WHO), the Partnership for Dengue Control (PDC), the Fondation Mérieux (FMx), the Dengue Vaccine Initiative (DVI), the International Vaccine Institute (IVI), the Asian Dengue Vaccination Advocacy (ADVA), the Southeast Asian Ministers of Education Organisation Tropical Medicine and Public Health Network (SEAMEO TROPMED) and the ASEAN Network for Drugs, Diagnostics, Vaccines and Traditional Medicines Innovation (ASEAN-NDI), among others.


Dengue Vaccine Initiative

The Dengue Vaccine Initiative (DVI) is a consortium of 4 organisations – The International Vaccine Institute (IVI), World Health Organisation (WHO), International Vaccine Access Center (IVAC) and Sabin Vaccine Institute (SVI). All these organisations bring essential and complementary capabilities to the consortium.

The IVI leads the consortium for field studies under the Evidence for Decision-Making component of DVI and prepares the focal country vaccine introduction cases and the global investment case. The WHO leads the development of information and guidance documents, and is involved in regulatory training activities. The IVAC leads activities related to the financing of dengue vaccine purchase including budget impact analysis and strategic demand forecasting. The SVI is a non-profit organisation that leads the DVI’s coalition-building, advocacy and communications activities.

DVI is committed to preventing dengue by laying the groundwork for dengue vaccine decision-making and introduction in endemic areas. It carries out its work under three broad objectives that are met with a comprehensive set of activities:

  1. Develop sound evidence for decision-making regarding the introduction of dengue vaccines
  2. Conduct policy and access-related activities to create an enabling environment at the national, regional, and global levels for the introduction of dengue vaccines
  3. Enable decision-making for countries interested in early adoption of a dengue vaccine




SEAMEO TROPMED Network is the regional cooperation network for education, training and research in tropical medicine and public health, which is parked under the Southeast Asian Ministers of Education. The Network aims to become and international forum for development in health and is working towards developing the capacity of institutions and individuals in delivering quality healthcare.  This network serves as a focal point in higher education and research in tropical medicine and public health.

The objectives of SEAMEO TROPMED are centred on training healthcare workers, supporting research on endemic and emerging diseases and advocating relevant health policies in order to empower communities with knowledge and encourage the use of tools for disease prevention thus minimizing the economic burden of health.



Partnership for Dengue Control - Fondation Mérieux

The Partnership for Dengue Control (PDC) is a unique global alliance of leaders in public health, international health agencies and dengue experts. The primary aim of PDC is to fight dengue by integrating innovative tools for prevention and control. They also work towards federating global community experts to support dengue-endemic countries.

PDC is hosted by Fondation Mérieux and supported by the prestigious Bill & Melinda Gates Foundation, the Carlos Slim Foundation, the Sabin Vaccine Institute and a number of partners from the vaccine and insecticide industries.
Fondation Mérieux is an independent family foundation that fights infectious diseases affecting developing countries. The FMx mission is to strengthen local capacities of developing countries so as to reduce the impact of infectious diseases on vulnerable populations.

The PDC supports the WHO’s Global Strategy for Dengue Prevention and Control 2012-2020 and is currently working at changing the paradigm for dengue control by building synergies among the many tools in development, including vaccines, therapeutics, insecticides and innovative approaches to mosquito control.